Company Overview and News
Stop missing out on important events!
Big Pharma has to build out pipelines in new areas, and M&A is a compelling alternative. (719-3)
Meanwhile, HCV sales have fallen off a cliff and can't get up without a ton of help from China, of which the company said nothing. (142-0)
The important, innovative biotech, CELG, has sold off again, closing the week a bit below the psychologically important $100 level. (112-0)
Last week's pullback in equities likely marks the end of the era of intense calm from 2016 to 2017.
Biotech sector starts off the year strong with multiple acquisitions and partnerships, beginning to usher in the long-awaited M&A boom. (654-6)
Celgene Corporation (CELG - Free Report) reported encouraging fourth-quarter 2017 results wherein both earnings and sales topped expectations. (93-1)
Today, Celgene announced the acquisition of Juno Therapeutics for $9B and CAR-T stocks continued their trajectory higher. (31-4)
Two major deals in the CAR-T space have raised excitement and at the forefront comes bluebird bio with not only CAR-T tech but gene therapy tech as well. (37-0)
U.S. equity markets have been on a tear since President Donald Trump’s election, owing to his pro-growth policies. However, various concerns over geopolitics and political stability in the United States bother the markets (read: U.S. ETFs in Focus as Market Cap Hits $30 trillion). (73-2)
Celgene Corporation (CELG - Free Report) announced that it will acquire Juno Therapeutics, Inc. (JUNO - Free Report) for $87 per share in cash, or a total of approximately $9 billion, net of cash and marketable securities acquired. The former already owns approximately 9.7% of outstanding shares of Juno. (93-0)
Buyout speculations related to Bluebird Bio, Inc. (BLUE - Free Report) are doing the rounds again. The rumors surfaced after biotech giant Celgene Corporation (CELG - Free Report) announced a $9 billion deal to buy Juno Therapeutics, Inc. (JUNO - Free Report) to add the latter’s CAR-T cancer therapy to its pipeline. (141-1)
bluebird bio, Inc.(BLUE - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 3.8% in the past one-month time frame. (54-0)
The CAR-T market is red hot with 2 drug approvals, 1 major buyout (Kite) and a second potential major buyout (Juno) occurring in the last 6 months. (80-0)
Per reports, biotech bigwig Celgene Corporation (CELG - Free Report) is looking to acquire smaller biotech Juno Therapeutics (JUNO - Free Report) . (93-0)
We feel that Litecoin is a safe bet, but that it may not have the highest returns in 2018.